Tenpoint Therapeutics Ltd. Submits New Drug Application to U.S. FDA for BRIMOCHOL™ PF for the Treatment of Presbyopia

LONDON & SEATTLE--(BUSINESS WIRE)-- #ophthalmology--Tenpoint Therapeutics, Ltd. (“Tenpoint”), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for BRIMOCHOL™ PF for the treatment of presbyopia, an age-related near-vision loss condition impacting approximately two billion people globally and 128 million peop